Search hospitals > Illinois > Princeton
Illinois CancerCare-Princeton
Claim this profilePrinceton, Illinois 61356
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Breast cancer
Conducts research for Cancer
Conducts research for Non-Small Cell Lung Cancer
377 reported clinical trials
2 medical researchers
Summary
Illinois CancerCare-Princeton is a medical facility located in Princeton, Illinois. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Illinois CancerCare-Princeton is involved with conducting 377 clinical trials across 471 conditions. There are 2 research doctors associated with this hospital, such as Bryan A. Faller and James L. Wade.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage II
Stage I
2Breast Cancer
Global LeaderStage IV
ER positive
HER2 negative
Top PIs
Bryan A. FallerCrossroads Cancer Center6 years of reported clinical research
Expert in Lung Cancer
Expert in Breast Cancer
239 reported clinical trials
297 drugs studied
James L. WadeDecatur Memorial Hospital4 years of reported clinical research
Studies Breast Cancer
Studies Bladder Cancer
11 reported clinical trials
20 drugs studied
Clinical Trials running at Illinois CancerCare-Princeton
Lung Cancer
Prostate Cancer
Breast Cancer
Breast cancer
Pancreatic Cancer
Cancer
Bladder Cancer
Kidney Cancer
Multiple Myeloma
Esophageal cancer
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Illinois CancerCare-Princeton?
Illinois CancerCare-Princeton is a medical facility located in Princeton, Illinois. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Illinois CancerCare-Princeton is involved with conducting 377 clinical trials across 471 conditions. There are 2 research doctors associated with this hospital, such as Bryan A. Faller and James L. Wade.
Where is Illinois CancerCare-Princeton located?
Illinois CancerCare, Princeton Location:
- Address: 530 Park Ave E, Princeton, IL 61356
- Location: Approximately 1.5 miles east of downtown Princeton, accessible via E Peru St.
Who should I call to ask about financial aid or insurance network?
**Illinois CancerCare-Princeton Financial Assistance:**
- For financial assistance, including support for transportation, home care, child care, and lodging, contact the CancerCare Hopeline at **800-813-4673**.
- For insurance-related inquiries, reach out to the Business Office at **(309) 243-3500** or toll-free at **(866) 662-6564**.
- For billing and insurance questions related to Princeton Health System, contact OSF HealthCare at **(800) 421-5700**.
What insurance does Illinois CancerCare-Princeton accept?
Illinois CancerCare-Princeton accepts a wide range of insurance plans, including but not limited to Medicare, Aetna (HMO, PPO, POS), BCBS of Illinois (PPO, POS, EPO, Classic Blue HMO, HMOI, Blue Advantage HMO), Beech Street PPO, Cigna/Great West Healthcare (HMO, PPO, POS, Open Access), and United Health Care. Other accepted insurances include Coventry/First Health/Personal Care, Humana (HMO, PPO, Choice POS, Choice Care Network), and Multiplan. It's important to confirm physician participation in your plan and understand any pre-certification requirements.
What awards or recognition has Illinois CancerCare-Princeton received?
Illinois CancerCare-Princeton, located in Princeton, Illinois, is distinguished by the Quality Oncology Practice Initiative (QOPI®) Certification Program for adhering to the highest national standards for cancer care quality. The hospital is also celebrated by the Alliance for Clinical Trials in Oncology for being among the top enrollers in clinical research nationwide, underscoring its dedication to pioneering new cancer treatments through clinical trials.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.